China has been the world's largest producer and exporter of active pharmaceutical ingredients (APIs) for over a decade, supplying approximately 40% of global API volume according to the 2025 China Pharmaceutical Industry Association report. For pharmaceutical companies in Europe, North America, Latin America, Southeast Asia, and Africa, sourcing APIs from China is not a peripheral option — it is a core supply chain strategy. This guide provides a structured, step-by-step framework for API procurement from Chinese manufacturers, designed for pharmaceutical buyers, regulatory affairs professionals, and supply chain managers operating in GMP-regulated markets.
China's API sector encompasses over 7,000 registered manufacturers, though the number of facilities operating at international GMP standards is significantly smaller — approximately 1,500-2,000 facilities hold GMP certificates recognized by foreign regulatory authorities. According to FDA data, as of January 2026, there were approximately 130 Chinese API manufacturing facilities with active Type II DMFs on file. The EDQM maintains a comparable number of active CEPs issued to Chinese manufacturers.
Key API production clusters are concentrated in Shandong, Zhejiang, Jiangsu, Hebei, and Sichuan provinces, with Shandong ranking first in total API production volume among all Chinese provinces. The industry has undergone significant consolidation since 2020, driven by stricter environmental regulations and the phasing out of older, non-compliant facilities. This consolidation has improved overall quality standards but has also reduced the number of available suppliers for certain niche APIs.
Supplier identification is the foundation of the entire sourcing process. Relying on a single source — such as one B2B platform — is insufficient. A systematic multi-channel approach reduces risk and increases the likelihood of finding qualified, GMP-compliant manufacturers.
Request the supplier's Drug Master File (DMF) number, CEP number, or registration certificates in your first email. Legitimate, audit-ready manufacturers provide this without hesitation. If a supplier is evasive about their regulatory filing status, remove them from your shortlist immediately.
Once you have a shortlist of 5-10 suppliers, request the following documentation package. A GMP-compliant manufacturer should be able to provide all of these within 3-5 business days:
| Document | What It Tells You | Red Flags |
|---|---|---|
| GMP Certificate | Current GMP compliance status, issuing authority, expiry date | Expired certificate, certificate from unrecognized authority, refusal to share |
| DMF Filing Confirmation | DMF number, type (Type II for APIs), filing date, status (active/inactive) | Citing a DMF from a different manufacturer, claiming "DMF-ready" without a filed number |
| CEP (Certificate of Suitability) | EDQM confirmation of pharmacopoeia monograph compliance, issuing date | Expired CEP, CEP for a different substance, reluctance to provide the certificate number |
| Recent Certificate of Analysis (CoA) | Actual batch data: assay, impurities, residual solvents, heavy metals, microbiological limits | Missing impurity data, results at specification limits with no margin, identical results across batches |
| Site Master File (SMF) | Facility overview: layout, equipment, utilities, quality system, personnel | Outdated SMF (more than 3 years old), generic SMF not specific to the facility |
| Manufacturing Process Description | Synthetic route, starting materials, solvents, key intermediates, yield | Undisclosed starting materials, use of Class 1 solvents (ICH Q3C), inconsistent yield claims |
| Stability Data | Long-term and accelerated stability per ICH Q1A, storage conditions, retest period | No data beyond 6 months, data only at 25C/60% RH but product labeled for Zone IV conditions |
| Residual Solvent Statement | ICH Q3C compliance declaration, list of solvents used with limits | Use of benzene, carbon tetrachloride, or 1,2-dichloroethane without justification |
Documentation review alone is not sufficient. A physical audit — either by your own quality assurance team or a qualified third-party auditor — is essential to verify that the documented quality system matches operational reality.
An on-site audit typically takes 2-3 days and should cover: production areas and equipment qualification, quality control laboratory and analytical instrument calibration, warehouse and material handling (receipt, sampling, storage, dispatch), HVAC and water systems, documentation system (batch records, deviation management, CAPA, change control), and personnel training records. Use a structured audit checklist aligned with ICH Q7 (GMP for Active Pharmaceutical Ingredients) or the relevant pharmacopoeia general chapter.
When travel is not feasible — either due to cost, time constraints, or geopolitical considerations — engage a third-party audit firm with pharmaceutical GMP expertise. Recognized firms include SGS, Intertek, Bureau Veritas, NSF International, and regional pharmaceutical consulting firms with Mandarin-speaking auditors. A third-party audit typically costs USD 3,000-8,000 per facility depending on scope and location within China. This is a fraction of the cost of a failed regulatory inspection triggered by supplier quality failures.
A paper-based qualification — relying solely on documents, a quality questionnaire, and video calls — is feasible if the supplier has a well-documented regulatory history (FDA inspected with no OAI classification, multiple active CEPs, or previous audit reports from reputable pharmaceutical companies that can be shared under confidentiality agreements). Document-only qualification should be followed by a physical audit before commercial-scale orders begin.
Request samples from your 2-4 top-ranked suppliers. Specify the following in your sample request:
Test samples against your in-house specifications and the supplier's CoA. Discrepancies between your results and the supplier's CoA — even within specification limits — warrant investigation. Consistent, tight results across multiple batches are more informative than a single passing result. If results are consistently at the edge of specification limits, that suggests a process capability problem that may lead to OOS results at commercial scale.
MOQs for APIs vary widely by product type and manufacturer scale. Commodity APIs (paracetamol, metformin, ibuprofen) may have MOQs in the 500-1,000 kg range. Specialty APIs (UDCA, oncology APIs, peptides) may have MOQs as low as 1-25 kg. For trial orders, most manufacturers will accommodate smaller quantities at a premium of 20-40% above bulk pricing. Negotiate a trial-to-commercial pricing pathway upfront — agree on what the price will be when your order volume reaches defined thresholds (e.g., 25 kg, 100 kg, 500 kg).
| Payment Method | Typical Terms | Risk Profile | Notes |
|---|---|---|---|
| T/T (Telegraphic Transfer) | 30/70 or 50/50 (deposit/balance) | Moderate — deposit at risk before shipment | Most common in China API trade. 30% deposit, 70% against B/L copy is standard. |
| L/C (Letter of Credit) | At sight, or 60/90/120 days | Low — bank guarantees payment if documents comply | Higher cost (bank fees). Standard for larger orders (USD 50,000+) and first-time transactions. |
| T/T against B/L Copy | 100% upon presenting B/L copy | Moderate-high for buyer | Common for established relationships. Goods have shipped but not yet received. |
| D/P (Documents against Payment) | Payment on document presentation | Low-moderate for buyer | Less common than T/T or L/C for API trade. |
The two most commonly used Incoterms in Chinese API trade are:
For air freight, FCA (Free Carrier) and CIP (Carriage and Insurance Paid To) replace FOB and CIF respectively.
A quality agreement is not optional for pharmaceutical API procurement. At minimum, it should define:
A trial order — typically 1-3 batches at pilot scale — should precede any commercial-scale commitment. The trial order serves several functions:
Treat the trial order as an audit in motion — document every interaction, every document received, and every deviation from agreed timelines or specifications. A supplier that performs poorly on a trial order will not improve at commercial scale.
| Term | Full Name | Jurisdiction | What It Means |
|---|---|---|---|
| DMF | Drug Master File | United States (FDA) | A confidential document submitted to the FDA containing detailed information about facilities, processes, and materials used in manufacturing. Type II DMF applies to APIs. Filing does not equal approval — the DMF must be reviewed (usually in connection with an ANDA/NDA referencing it) and found adequate. |
| CEP | Certificate of Suitability to the European Pharmacopoeia | European Union (EDQM) | Certifies that an API is suitably controlled by the relevant European Pharmacopoeia monograph. A CEP simplifies the API section of a marketing authorization application in EU member states. It is reviewed and granted by the EDQM, not passively filed like a DMF. |
| ASMF | Active Substance Master File | European Union | Formerly known as EDMF. The EU equivalent of a DMF, used when a CEP is not available. Submitted as part of a marketing authorization application. Divided into Applicant's Part (open) and Restricted Part (confidential). |
| JDMF | Japan Drug Master File | Japan (PMDA) | The Japanese equivalent of a DMF. Required for APIs used in drug products marketed in Japan. Registration and review by the PMDA. |
| WC | Written Confirmation | European Union | Required for APIs manufactured in non-EU countries and imported into the EU. Confirms that GMP standards equivalent to EU GMP are applied. Issued by the competent authority of the exporting country. |
The most successful API sourcing relationships transcend transactional procurement. Long-term partnerships deliver value through:
This guide reflects industry practices as of July 2026. Regulatory requirements, trade policies, and market conditions change. Verify current requirements with the relevant regulatory authority (FDA, EMA, PMDA, NMPA) before making sourcing decisions.
This is general guidance and does not constitute legal, regulatory, or commercial advice. Specific situations require professional consultation.
References: ICH Q7 (GMP for APIs), ICH Q3C (Residual Solvents), ICH Q3D (Elemental Impurities), FDA Guidance for Industry: DMFs, EDQM CEP Guidelines, 2025 China Pharmaceutical Industry Association Report.
Page last updated: July 2026
KingWish holds active FDA DMF and EDQM CEP filings for UDCA. Contact us for supplier qualification documentation.
| Global API Share | China ~40% |
|---|---|
| GMP API Facilities | ~1,500-2,000 |
| Common Incoterms | FOB, CIF, FCA, CIP |
| Common Payment | T/T, L/C |
| Key Trade Show | CPHI China (June) |
| 3rd-Party Audit Cost | USD 3,000-8,000 |